Objective In England, the National Health Service commissioned a National Management Service for children with primary ciliary dyskinesia (PCD). The aims of this study were to describe the health of children seen in this Service and compare lung function to children with cystic fibrosis (CF).
Design Multi-centre service evaluation of the English National Management PCD Service.
Setting Four nationally commissioned PCD centres in England.
Patients 333 children with PCD reviewed in the Service in 2015; lung function data were also compared with 2970 children with CF.
Results Median age at diagnosis for PCD was 2.6 years, significantly lower in children with situs inversus (1.0 vs 6.0 years, p<0.001). Compared with national data from the CF Registry, mean (SD) %predicted forced expiratory volume in one second (FEV1) was 76.8% in PCD (n=240) and 85.0% in CF, and FEV1 was lower in children with PCD up to the age of 15 years. Approximately half of children had some hearing impairment, with 26% requiring hearing aids. Children with a lower body mass index (BMI) had lower FEV1 (p<0.001). One-third of children had positive respiratory cultures at review, 54% of these grew Haemophilus influenzae.
Conclusions We provide evidence that children with PCD in England have worse lung function than those with CF. Nutritional status should be considered in PCD management, as those with a lower BMI have significantly lower FEV1. Hearing impairment is common but seems to improve with age. Well-designed and powered randomised controlled trials on management of PCD are needed to inform best clinical practice.
- primary ciliary dyskinesia
- lung function
- cystic Fibrosis
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Collaborators Members of the English National Children’s PCD Management Service include: Amanda Harris, Amanda Friend, Victoria Keenan, Hannah Wilkins, Hasnaa Ismail-Koch, Andrea Burgess, Samantha Packham, Patricia Goggin, Gemma Marsh, Laura Baynton, Michael Leshen, Sarah Ollosson, Nicola Collins, Peter Rea, Ann-Louise McDermott, Amanda Parsons, Rajinder Kang, Nicola Lloyd, Alison Truscott, Lynne Schofield, l Knight.
Contributors WW, JSL, SC, CH, PC, EM, MN, PK, CO’C and MW developed the concept and design of the study. WW and BR are responsible for the integrity of the study and data; BR led standardised clinical data collection, data management and statistical analyses; WW and BR drafted the manuscript; SB, BR, SC, PK, PC, EM, RH, AS, PG, MN and WW extracted of clinical data from patient record; WW, JSL, SC, CH, PC, EM, MN, PK, CO’C and MW led the diagnostic service and annual reviews at their respective centres; JSL provided guidance and critically reviewed the manuscript at an early draft. All co-authors critically reviewed and approved the final manuscript.
Funding The National PCD Service is commissioned and funded by NHS England. Research in Southampton is supported by NIHR Southampton Biomedical Research Centre and NIHR Wellcome Trust Clinical Research Facility. Research in Royal Brompton Hospital is supported by the NHLI, Imperial College London. Research in GOSH is supported by the NIHR GOSH BRC. Research in the University Hospitals of Leicester NHS Trust is supported by University of Leicester, Leicester. Research in Birmingham Women’s and Children’s Hospital NHS Trust is supported by the University of Birmingham and Wellcome Trust Clinical Research Facility.
Disclaimer The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
Competing interests JL reports grants, personal fees and non-financial support from Aerocrine/ Circassia, grants and personal fees from Vertex, grants from Parion, outside the submitted work. SC reports grants, personal fees and non-financial support from Vertex Pharmaceuticals, grants and other from Chiesi Pharmaceuticals, other from Pharmaxis Pharmaceuticals, personal fees from Actavis Pharmaceuticals, other from Profile Pharma, outside the submitted work.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available upon reasonable request. Data will be made available upon reasonable request by contacting the corresponding author.